DE69840746D1 - Verfahren zur behandlung der "trockenes auge" krankheit mit purinergischen rezeptoragonisten - Google Patents

Verfahren zur behandlung der "trockenes auge" krankheit mit purinergischen rezeptoragonisten

Info

Publication number
DE69840746D1
DE69840746D1 DE69840746T DE69840746T DE69840746D1 DE 69840746 D1 DE69840746 D1 DE 69840746D1 DE 69840746 T DE69840746 T DE 69840746T DE 69840746 T DE69840746 T DE 69840746T DE 69840746 D1 DE69840746 D1 DE 69840746D1
Authority
DE
Germany
Prior art keywords
triphosphate
treatment
subject
disclosed
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840746T
Other languages
German (de)
English (en)
Inventor
Benjamin R Yerxa
Karla M Jacobus
William Pendergast
Janet L Rideout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inspire Pharmaceuticals Inc
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25170925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69840746(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69840746D1 publication Critical patent/DE69840746D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69840746T 1997-02-06 1998-02-06 Verfahren zur behandlung der "trockenes auge" krankheit mit purinergischen rezeptoragonisten Expired - Lifetime DE69840746D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/797,472 US5900407A (en) 1997-02-06 1997-02-06 Method of treating dry eye disease with uridine triphosphates and related compounds
PCT/US1998/002701 WO1998034593A1 (en) 1997-02-06 1998-02-06 Method of treating dry eye disease with purinergic receptor agonists

Publications (1)

Publication Number Publication Date
DE69840746D1 true DE69840746D1 (de) 2009-05-28

Family

ID=25170925

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840746T Expired - Lifetime DE69840746D1 (de) 1997-02-06 1998-02-06 Verfahren zur behandlung der "trockenes auge" krankheit mit purinergischen rezeptoragonisten

Country Status (19)

Country Link
US (6) US5900407A (enExample)
EP (1) EP1003474B1 (enExample)
JP (3) JP3652707B2 (enExample)
KR (1) KR100378443B1 (enExample)
CN (1) CN1151775C (enExample)
AT (1) ATE428400T1 (enExample)
AU (1) AU735684B2 (enExample)
BR (1) BR9809562A (enExample)
CA (1) CA2280183C (enExample)
DE (1) DE69840746D1 (enExample)
DK (1) DK1003474T3 (enExample)
ES (1) ES2325892T3 (enExample)
ID (1) ID23375A (enExample)
MY (1) MY120023A (enExample)
NO (1) NO329118B1 (enExample)
NZ (1) NZ337405A (enExample)
PT (1) PT1003474E (enExample)
WO (1) WO1998034593A1 (enExample)
ZA (1) ZA98979B (enExample)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US6673779B2 (en) * 1996-03-27 2004-01-06 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
US6420347B1 (en) * 1997-03-27 2002-07-16 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6696425B2 (en) * 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6921755B2 (en) * 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6596725B2 (en) 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US7078391B2 (en) 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
KR20010013797A (ko) * 1997-07-25 2001-02-26 인스파이어 파마슈티컬스 인코퍼레이티드 디(우리딘 5'-테트라포스페이트) 염 및 그의 제조방법과용도
TW593331B (en) * 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
US6548658B2 (en) * 1997-07-25 2003-04-15 Inspire Pharmaceuticals, Inc. Di-(uridine 5′)-tetraphosphate and salts thereof
JP4633927B2 (ja) * 1998-05-22 2011-02-16 インスパイアー ファーマシューティカルズ,インコーポレイティド 治療用ジヌクレオチドおよび誘導体
EP1140967A1 (en) * 1998-12-23 2001-10-10 University Of North Carolina At Chapel Hill Targeted gene transfer using g protein coupled receptors
WO2000050024A2 (en) * 1999-02-26 2000-08-31 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
DE60021629T2 (de) * 1999-06-30 2006-01-05 Yamasa Corp., Choshi Dinukleotid-Kristalle
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6723737B1 (en) * 1999-10-20 2004-04-20 Eliezer Rapaport Methods, pharmaceutical and therapeutic compostions for administering adenosine
WO2001028528A1 (en) * 1999-10-20 2001-04-26 Eliezer Rapaport Methods, pharmaceutical and therapeutic compositions for administering adenosine
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6864243B1 (en) 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
AU6064301A (en) * 2000-05-30 2001-12-11 Santen Pharmaceutical Co Ltd Ectocornea extension promoters
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US6555675B2 (en) 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
JP3945625B2 (ja) * 2001-03-30 2007-07-18 株式会社イーエムアイ 角膜上皮障害モデル動物及びそのモデル動物を用いた薬剤の評価方法並びにその評価方法を用いて選択された薬剤
US7629329B2 (en) 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
GB2394419B (en) 2001-06-25 2005-09-07 Inspire Pharmaceuticals Inc Joint lubrication with p2y purinergic receptor agonists
CN1228053C (zh) * 2001-09-11 2005-11-23 参天制药株式会社 含有二尿苷磷酸的滴眼液
WO2003022858A2 (de) * 2001-09-11 2003-03-20 Nascacell Gmbh Verfahren zum screenen von inhibitoren für die protein-protein-wechselwirkung sowie ribozyme hierzu
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
WO2003030894A1 (en) * 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye
US20030109488A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
CA2462272A1 (en) * 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue
CN1612739A (zh) * 2001-11-06 2005-05-04 印斯拜尔药品股份有限公司 治疗或预防炎性疾病的方法
US7084128B2 (en) * 2002-01-18 2006-08-01 Inspire Pharmaceuticals, Inc. Method for reducing intraocular pressure
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1560540A4 (en) * 2002-10-18 2008-03-19 Molichem Medicines Inc METHOD FOR TREATING DRY EYES WITH LANTIBIOTICS
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
EP1753445A4 (en) * 2004-05-06 2009-05-20 Molichem Medicines Inc TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS
US7326683B2 (en) * 2004-05-06 2008-02-05 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
RU2287159C1 (ru) * 2005-03-14 2006-11-10 Уральская государственная медицинская академия дополнительного образования Способ прогнозирования течения синдрома "сухого глаза"
RU2271184C1 (ru) * 2005-06-02 2006-03-10 Федеральное государственное учреждение "Всероссийский центр глазной и пластической хирургии Федерального агентства по здравоохранению и социальному развитию" Способ хирургического лечения синдрома сухого глаза
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
KR100870104B1 (ko) 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
KR101037095B1 (ko) * 2006-01-27 2011-05-26 캔-파이트 바이오파마 리미티드 건성안 장애의 치료를 위한 아데노신 a3 수용체 아고니스트
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
US10117906B2 (en) * 2009-01-09 2018-11-06 The Schepens Eye Research Institute, Inc. Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra
EP2538965B1 (en) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
ES2634551T3 (es) 2010-04-03 2017-09-28 Praful Doshi Métodos para revestir una lente de contacto
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
CN103096929A (zh) 2010-09-10 2013-05-08 参天制药株式会社 以组合p2y2受体激动剂和透明质酸或其盐为特征的干眼症治疗剂、干眼症的治疗方法、及干眼症治疗剂的应用
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
JP2013542838A (ja) 2010-11-16 2013-11-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ドライアイを治療するためのシステムおよび方法
JP2012149057A (ja) 2010-12-28 2012-08-09 Santen Pharmaceut Co Ltd ジクアホソル含有点眼液およびその製造方法、不溶性析出物発生の抑制方法
KR101943593B1 (ko) * 2011-04-06 2019-01-30 케이엘에이-텐코 코포레이션 공정 제어를 개선하기 위한 품질 메트릭 제공 방법 및 시스템
SG10201607872PA (en) 2012-03-26 2016-11-29 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
US9717627B2 (en) 2013-03-12 2017-08-01 Oculeve, Inc. Implant delivery devices, systems, and methods
AU2014253754C1 (en) 2013-04-19 2015-07-30 Oculeve, Inc. Nasal stimulation devices and methods
CN111298285A (zh) 2014-02-25 2020-06-19 奥库利维公司 用于鼻泪刺激的聚合物制剂
EP3171928B1 (en) 2014-07-25 2020-02-26 Oculeve, Inc. Stimulation patterns for treating dry eye
AU2015335774B2 (en) 2014-10-22 2020-07-16 Oculeve, Inc. Implantable nasal stimulator systems and methods
MX2017005204A (es) 2014-10-22 2017-12-14 Oculeve Inc Dispositivos y métodos de estimulación para tratar el ojo seco.
CA2965514A1 (en) 2014-10-22 2016-04-28 Oculeve, Inc. Contact lens for increasing tear production
CN107635565A (zh) 2015-06-05 2018-01-26 参天制药株式会社 以向佩戴有软性隐形眼镜的干眼症患者的眼中滴入的方式使用为特征的干眼症治疗剂
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
EP3452166A4 (en) 2016-05-02 2019-12-18 Oculeve, Inc. INTRANASAL STIMULATION FOR THE TREATMENT OF DISEASES OF MEIBOM'S GLANDS AND BLEPHARITIS
RU2019118600A (ru) 2016-12-02 2021-01-11 Окулив, Инк. Аппарат и способ составления прогноза синдрома сухого глаза и рекомендаций по лечению
TWI833406B (zh) * 2018-02-28 2024-02-21 日商參天製藥股份有限公司 含有迪夸弗索(Diquafosol)及陽離子性聚合物之眼科用組合物
TWI833913B (zh) 2019-02-27 2024-03-01 日商參天製藥股份有限公司 含有迪夸弗索(diquafosol)或其鹽、乙烯系高分子及纖維素系高分子之眼科用組合物
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
KR20240049646A (ko) * 2019-08-27 2024-04-16 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물
KR20210110055A (ko) * 2020-02-28 2021-09-07 주식회사 종근당바이오 P1, p4-디(우리딘 5'-)테트라포스페이트 나트륨염 4 수화물 결정형 a의 제조방법
KR102548710B1 (ko) 2020-12-24 2023-06-28 주식회사 종근당 디쿠아포솔 또는 이의 약제학적으로 허용가능한 염과 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
JP2025528009A (ja) 2022-07-15 2025-08-26 ドーシ,プラフル 医薬品と薬剤などの不安定な構成要素の安定剤とを含むコンタクトレンズを作製及び使用する方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2330902A1 (de) * 1973-06-18 1975-03-20 Helmut Dr Med Zander Heilungsfoerderndes und vorbeugendes, zur aeusserlichen oertlichen anwendung auf der haut und im auge fuer mensch und tier bestimmtes arznei- bzw. hautpflegemittel
US4380239A (en) 1979-12-20 1983-04-19 The Hospital For Sick Children Intubation of lacrimal ducts
US4658816A (en) 1984-11-14 1987-04-21 Concept Incorporated Lighted canaliculus intubation sets
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4868154A (en) * 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
US5062831A (en) 1988-09-28 1991-11-05 Griffiths John D Catheter for use in the surgical correction of a nasolacrimal duct obstruction
US4921485A (en) 1988-09-28 1990-05-01 Griffiths John D Catheter for use in the surgical correction of a nasolacrimal duct obstruction
US5169386A (en) 1989-09-11 1992-12-08 Bruce B. Becker Method and catheter for dilatation of the lacrimal system
US5021043A (en) 1989-09-11 1991-06-04 C. R. Bard, Inc. Method and catheter for dilatation of the lacrimal system
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5345948A (en) 1993-04-08 1994-09-13 Donnell Jr Francis E O Method of performing translactrimal laser dacryocystorhinostomy
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
AU727314B2 (en) * 1996-03-27 2000-12-07 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6921755B2 (en) 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6696425B2 (en) * 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
TW567456B (en) * 2001-02-15 2003-12-21 Au Optronics Corp Apparatus capable of improving flicker of thin film transistor liquid crystal display
FR2904554B1 (fr) * 2006-08-04 2010-11-05 Zheng Xu Lipides moleculaires heterogenes cytotropes (lmhc), procede de preparation, et methodes de traitement de patients porteurs de cancers multiples

Also Published As

Publication number Publication date
AU6324198A (en) 1998-08-26
US7235535B2 (en) 2007-06-26
PT1003474E (pt) 2009-06-26
NZ337405A (en) 2001-07-27
DK1003474T3 (da) 2009-07-20
CA2280183C (en) 2008-04-22
ATE428400T1 (de) 2009-05-15
US5900407A (en) 1999-05-04
US6916794B2 (en) 2005-07-12
US20100330164A1 (en) 2010-12-30
US6887858B1 (en) 2005-05-03
JP2005015491A (ja) 2005-01-20
JP3652707B2 (ja) 2005-05-25
JP2010111676A (ja) 2010-05-20
JP2001504858A (ja) 2001-04-10
BR9809562A (pt) 2001-10-02
KR100378443B1 (ko) 2003-03-29
MY120023A (en) 2005-08-30
US8097600B2 (en) 2012-01-17
CN1250369A (zh) 2000-04-12
ES2325892T3 (es) 2009-09-23
NO993777L (no) 1999-10-05
JP4664027B2 (ja) 2011-04-06
WO1998034593A1 (en) 1998-08-13
CN1151775C (zh) 2004-06-02
CA2280183A1 (en) 1998-08-13
US20020103157A1 (en) 2002-08-01
US20080009463A1 (en) 2008-01-10
ID23375A (id) 2000-04-20
KR20000070848A (ko) 2000-11-25
JP5373576B2 (ja) 2013-12-18
US7759322B2 (en) 2010-07-20
HK1025915A1 (en) 2000-12-01
NO329118B1 (no) 2010-08-30
AU735684B2 (en) 2001-07-12
NO993777D0 (no) 1999-08-04
EP1003474A1 (en) 2000-05-31
EP1003474B1 (en) 2009-04-15
ZA98979B (en) 1999-02-19
US20050197316A1 (en) 2005-09-08

Similar Documents

Publication Publication Date Title
DE69840746D1 (de) Verfahren zur behandlung der "trockenes auge" krankheit mit purinergischen rezeptoragonisten
MXPA01008547A (es) Metodo para promover la hidratacion de mucosas con ciertos difosfatos de uridina, adenina y citidina, y analogos de estos.
WO2001080844A3 (en) Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
ATE335492T1 (de) Verfahren zur behandlung der ziliardyskinesie mit uridintriphosphaten und verwandten verbindungen
AU2003287005B2 (en) Vaginal health products
JPS62246524A (ja) ホスホジエステラ−ゼインヒビタ−及び環状ヌクレオチド類似体による涙分泌の刺激
DE69633449D1 (de) Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten
ATE225663T1 (de) Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
ATE261982T1 (de) Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
WO1998003182A3 (en) Use of uridine triphosphates and related compounds for the prevention and treatment of pneumonia in immobilized patients
CA2259552A1 (en) Method of treating sinusitis with uridine triphosphates and related compounds
KR920703041A (ko) 통증을 수반하는 염증성 또는 알레르기성 질환치료에 사용되는 성분물과 그 방법
US7056889B2 (en) Compounds that bind P2Y2 or P2Y1 receptors
IT1313585B1 (it) Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti.
US7256183B2 (en) Method for treating or preventing inflammatory diseases
DE60008589D1 (de) Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten
ES2173027B2 (es) Uso de nucleotidos en el tratamiento del glaucoma y la hipertension ocular.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition